AU2008308519B2 - Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer - Google Patents
Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer Download PDFInfo
- Publication number
- AU2008308519B2 AU2008308519B2 AU2008308519A AU2008308519A AU2008308519B2 AU 2008308519 B2 AU2008308519 B2 AU 2008308519B2 AU 2008308519 A AU2008308519 A AU 2008308519A AU 2008308519 A AU2008308519 A AU 2008308519A AU 2008308519 B2 AU2008308519 B2 AU 2008308519B2
- Authority
- AU
- Australia
- Prior art keywords
- nilvadipine
- composition
- enriched
- disease
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97795307P | 2007-10-05 | 2007-10-05 | |
| US60/977,953 | 2007-10-05 | ||
| US4610908P | 2008-04-18 | 2008-04-18 | |
| US61/046,109 | 2008-04-18 | ||
| PCT/US2008/078786 WO2009046323A1 (en) | 2007-10-05 | 2008-10-03 | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2008308519A1 AU2008308519A1 (en) | 2009-04-09 |
| AU2008308519A2 AU2008308519A2 (en) | 2010-04-29 |
| AU2008308519B2 true AU2008308519B2 (en) | 2014-09-11 |
Family
ID=40523447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008308519A Ceased AU2008308519B2 (en) | 2007-10-05 | 2008-10-03 | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8236346B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2214666B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5411145B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101417200B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101883564B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008308519B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0817516A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2701620C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2214666T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2449594T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010003669A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ584729A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2214666T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2490014C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI500422B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009046323A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140286910A1 (en) * | 2013-03-19 | 2014-09-25 | Nikolai Tankovich | Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity |
| CN112826794B (zh) | 2019-11-06 | 2022-02-11 | 上海交通大学医学院 | 一种靶向修复神经血管病变的纳米复合物及其制备与应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0321636A2 (en) * | 1987-06-12 | 1989-06-28 | American Cyanamid Company | Enhancers for the transdermal flux of certain 1,4-Dihydropyridine derivatives |
| US5508413A (en) * | 1987-08-27 | 1996-04-16 | Fujisawa Pharmaceutical Co., Ltd. | (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate |
| US20050009885A1 (en) * | 2003-05-15 | 2005-01-13 | Mullan Michael J. | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338322A (en) | 1975-07-02 | 1982-07-06 | Fujisawa Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same |
| JPS6038322A (ja) | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンa物質含有易溶性固形製剤 |
| JPS61129140A (ja) | 1984-11-27 | 1986-06-17 | Nitto Electric Ind Co Ltd | 医薬組成物 |
| GB8431119D0 (en) | 1984-12-10 | 1985-01-16 | Fujisawa Pharmaceutical Co | Anti-arteriosclerotic composition |
| US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| DE3877630T2 (de) | 1987-06-12 | 1993-06-03 | American Cyanamid Co | Transkutane verabreichung von pharmazeutika. |
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US5045553A (en) | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
| US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
| US5160734A (en) | 1987-11-25 | 1992-11-03 | American Cyanamid Company | Sustained release delivery system for substituted dihydropyridine calcium channel blockers |
| DE3871343D1 (de) | 1987-11-25 | 1992-06-25 | American Cyanamid Co | System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridin-calciumantagonisten. |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP2718105B2 (ja) | 1988-10-27 | 1998-02-25 | 藤沢薬品工業株式会社 | (+)−2−シアノ−6−メチル−4−(3−ニトロフェニル)−1,4−ジヒドロピリジン−3,5−ジカルボン酸5−イソプロピル3−メチルの光安定性結晶 |
| AU5419690A (en) | 1989-03-31 | 1990-11-05 | Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| JPH0381262A (ja) | 1989-08-23 | 1991-04-05 | Yamanouchi Pharmaceut Co Ltd | ジヒドロピリジン系カルシウム拮抗薬の光学活性体の製造法 |
| JP2867462B2 (ja) | 1989-09-12 | 1999-03-08 | 藤沢薬品工業株式会社 | 経皮吸収用製剤 |
| JP2920956B2 (ja) | 1989-10-06 | 1999-07-19 | 藤沢薬品工業株式会社 | ニルバジピン含有持続性錠剤 |
| US5258393A (en) | 1990-02-21 | 1993-11-02 | Fujisawa Pharmaceutical Co., Ltd. | Use of a dihydropyridine compound for improving inner ear microcirculation |
| EP0557290A1 (en) | 1990-08-23 | 1993-09-01 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
| WO1993005770A1 (fr) | 1991-09-20 | 1993-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Preparation a longue duree d'action |
| JPH05139974A (ja) | 1991-11-26 | 1993-06-08 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンa物質含有易溶性固体分散体の製造法 |
| US5834496A (en) | 1991-12-02 | 1998-11-10 | Sepracor, Inc. | Methods for treating hypertension using optically pure S(-) felodipine |
| DE4141646A1 (de) | 1991-12-17 | 1993-06-24 | Klinge Co Chem Pharm Fab | Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| DE4229805A1 (de) | 1992-09-07 | 1994-03-24 | Werner E G Prof Dr Mueller | Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden |
| US5721263A (en) | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| AU682192B2 (en) * | 1993-06-30 | 1997-09-25 | Fujisawa Pharmaceutical Co., Ltd. | Encapsulated medicine |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CA2252962A1 (en) | 1996-04-26 | 1997-11-06 | Fujisawa Pharmaceutical Co., Ltd. | Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines |
| US6271259B1 (en) | 1996-05-07 | 2001-08-07 | Ito En, Ltd. | Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death |
| KR100222306B1 (ko) | 1996-11-20 | 1999-10-01 | 이병언 | 닐바디핀 속효성 고형제제 및 이의 제조방법 |
| US6541479B1 (en) * | 1997-12-02 | 2003-04-01 | Massachusetts College Of Pharmacy | Calcium channel blockers |
| EP1085890A1 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Novel sodium channel drugs and uses |
| JP2002517440A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | 新規カルシウムチャンネル薬物および用途 |
| KR20040078140A (ko) | 1998-07-10 | 2004-09-08 | 노파르티스 아게 | 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제 |
| WO2001064250A1 (en) | 2000-03-03 | 2001-09-07 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof |
| BR0109991A (pt) | 2000-04-11 | 2003-05-27 | Sankyo Co | Composição farmacêutica |
| JP2001335483A (ja) | 2000-05-30 | 2001-12-04 | Nichiko Pharmaceutical Co Ltd | ニルバジピン含有製剤 |
| ATE357257T1 (de) | 2000-07-27 | 2007-04-15 | Pharmacia Corp | Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen |
| JP3968687B2 (ja) | 2000-09-13 | 2007-08-29 | 東和薬品株式会社 | 易吸収性ニルバジピン錠 |
| JP3470096B2 (ja) | 2000-09-19 | 2003-11-25 | 沢井製薬株式会社 | ニルバジピン含有易溶性固形製剤およびその製造法 |
| AU2002227957A1 (en) | 2000-12-19 | 2002-07-01 | Merck Patent Gmbh | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| BR0115995A (pt) | 2000-12-19 | 2004-01-13 | Merck Patent Gmbh | Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina |
| US7083642B2 (en) | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
| CA2333494A1 (en) | 2001-02-01 | 2002-08-01 | Vasogen Ireland Limited | Blood brain barrier modulation |
| WO2002096415A2 (en) | 2001-05-25 | 2002-12-05 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
| DE60227679D1 (de) | 2001-09-11 | 2008-08-28 | Asahi Kasei Pharma Corp | Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| KR20100137026A (ko) | 2002-05-17 | 2010-12-29 | 노파르티스 아게 | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물 |
| TW200306799A (en) | 2002-05-17 | 2003-12-01 | Novartis Ag | Combination of organic compounds |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| JP2003146878A (ja) | 2002-11-22 | 2003-05-21 | Sawai Pharmaceutical Co Ltd | ニルバジピン含有易溶性固形製剤およびその製造法 |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| KR20050101537A (ko) | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 |
| JP2004002460A (ja) | 2003-07-29 | 2004-01-08 | Towa Yakuhin Kk | 易吸収性ニルバジピン錠の製造法 |
| WO2009046338A1 (en) * | 2007-10-05 | 2009-04-09 | Roskamp Research Llc | Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer |
-
2008
- 2008-10-03 CN CN200880118761XA patent/CN101883564B/zh not_active Expired - Fee Related
- 2008-10-03 MX MX2010003669A patent/MX2010003669A/es active IP Right Grant
- 2008-10-03 ES ES08836256.1T patent/ES2449594T3/es active Active
- 2008-10-03 DK DK08836256.1T patent/DK2214666T3/da active
- 2008-10-03 JP JP2010528172A patent/JP5411145B2/ja not_active Expired - Fee Related
- 2008-10-03 BR BRPI0817516-0A patent/BRPI0817516A2/pt not_active Application Discontinuation
- 2008-10-03 NZ NZ584729A patent/NZ584729A/xx not_active IP Right Cessation
- 2008-10-03 US US12/245,354 patent/US8236346B2/en not_active Expired - Fee Related
- 2008-10-03 EP EP08836256.1A patent/EP2214666B1/en active Active
- 2008-10-03 PL PL08836256T patent/PL2214666T3/pl unknown
- 2008-10-03 CA CA2701620A patent/CA2701620C/en not_active Expired - Fee Related
- 2008-10-03 AU AU2008308519A patent/AU2008308519B2/en not_active Ceased
- 2008-10-03 TW TW097138351A patent/TWI500422B/zh not_active IP Right Cessation
- 2008-10-03 KR KR1020107009874A patent/KR101417200B1/ko not_active Expired - Fee Related
- 2008-10-03 RU RU2010117634/15A patent/RU2490014C2/ru active
- 2008-10-03 WO PCT/US2008/078786 patent/WO2009046323A1/en not_active Ceased
-
2010
- 2010-02-01 US US12/697,436 patent/US8236347B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0321636A2 (en) * | 1987-06-12 | 1989-06-28 | American Cyanamid Company | Enhancers for the transdermal flux of certain 1,4-Dihydropyridine derivatives |
| US5508413A (en) * | 1987-08-27 | 1996-04-16 | Fujisawa Pharmaceutical Co., Ltd. | (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate |
| US20050009885A1 (en) * | 2003-05-15 | 2005-01-13 | Mullan Michael J. | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2490014C2 (ru) | 2013-08-20 |
| EP2214666A1 (en) | 2010-08-11 |
| RU2010117634A (ru) | 2011-11-10 |
| CA2701620A1 (en) | 2009-04-09 |
| CA2701620C (en) | 2014-12-09 |
| WO2009046323A1 (en) | 2009-04-09 |
| JP5411145B2 (ja) | 2014-02-12 |
| US8236347B2 (en) | 2012-08-07 |
| US20090092667A1 (en) | 2009-04-09 |
| JP2010540661A (ja) | 2010-12-24 |
| US8236346B2 (en) | 2012-08-07 |
| US20100183711A1 (en) | 2010-07-22 |
| ES2449594T3 (es) | 2014-03-20 |
| EP2214666A4 (en) | 2010-12-08 |
| BRPI0817516A2 (pt) | 2015-06-16 |
| NZ584729A (en) | 2012-12-21 |
| AU2008308519A1 (en) | 2009-04-09 |
| EP2214666B1 (en) | 2013-12-11 |
| PL2214666T3 (pl) | 2014-06-30 |
| KR101417200B1 (ko) | 2014-08-01 |
| DK2214666T3 (da) | 2014-01-27 |
| MX2010003669A (es) | 2010-11-25 |
| TW200920364A (en) | 2009-05-16 |
| CN101883564B (zh) | 2013-10-16 |
| AU2008308519A2 (en) | 2010-04-29 |
| KR20100067683A (ko) | 2010-06-21 |
| TWI500422B (zh) | 2015-09-21 |
| CN101883564A (zh) | 2010-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2829039C (en) | Effective amounts of (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods thereof | |
| AU2010249015A1 (en) | Treatment of MCI and Alzheimer's disease | |
| JP2012526844A5 (cg-RX-API-DMAC7.html) | ||
| JP2013526518A (ja) | Mciおよびアルツハイマー病の処置 | |
| US9968574B2 (en) | Treatment of MCI and Alzheimer's disease | |
| US7732467B2 (en) | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis | |
| CA2701620C (en) | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer | |
| US20100093810A1 (en) | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis | |
| WO2009046338A1 (en) | Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer | |
| EP1874311B1 (en) | A method for preventing, delaying or reverting abnormal amyloid deposition | |
| HK1092358B (en) | Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis | |
| ITPD20060014A1 (it) | Metodo per alimentare l'efflusso dal sistema nervoso di peptidi amiloidei |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 APR 2010 |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ALZHEIMER'S INSTITUTE OF AMERICA, INC. Free format text: FORMER APPLICANT(S): ROSKAMP RESEARCH LLC |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |